Immunization

The ACIP recommendations are designed to improve access to RSV vaccination, emphasizing the need to get vaccinated.

The committee, after being presented evidence by the working group, recommended the vaccine for adults aged 65 and older and those 19 or older who have current recommendations to receive a pneumococcal vaccine.

Staying updated on travel vaccines and applying sunscreen are examples of summer health counseling tips

Pharmacies can position themselves as leaders in immunization services.

V116 (Capvaxive; Merck) elicited higher immune responses than the comparator for the serotypes that are unique to the vaccine, according to studies submitted to the FDA.

The SCDM model demands more than the traditional roles assigned to pharmacists, requiring an enhanced level of patient engagement, medical knowledge, and legal authority to implement effectively

The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk.

Serotypes associated with V116 (Merck & Co. Inc.) had higher clinical and economic burden for individuals with invasive pneumococcal disease.

A single dose of the vaccine showed long-lasting protection against RSV-associated lower respiratory tract disease in older adults.

The immunizing technicians stated they had greater job satisfaction and had a greater sense of being valuable pharmacy members

This is Moderna's second mRNA vaccine approval and the first mRNA vaccine approved for an indication other than COVID-19.

Pediatric patients with rheumatic disease, such as systemic lupus erythematosus, mixed connective tissue disease, juvenile dermatomyositis, and systemic vasculitis are at an increased risk of serious infection.

As Summer Approaches, Many Will Be Planning Vacations and Trips Abroad

This is the first approval of an EB virus-related mRNA therapeutic cancer vaccine and is a landmark achievement in future research on cancer treatment.

Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Additionally, undocumented Latinx patients were also more likely to have at least 1 prior COVID-19 infection.

Notable contributions from female leaders in the pharmaceutical industry demonstrate the exceptional competence of women in vaccine innovation.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

Sharing data and a personal recommendation can make a difference in a patient’s life

The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety

The 5-in-1 meningococcal ABCWY vaccine candidate has an assigned Prescription Drug User Fee Act action date of February 14, 2025.

Investigators also found that the pneumococcal conjugate vaccine 13 protected against nasopharyngeal carriage in children and provided some indirect protection for adults.

Although the vaccine has not yet been tested in humans, it demonstrated 100% efficacy in protecting primates who were injected with human Marburg virus disease.

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

It is unclear why the vaccines were less effective in women, but researchers note that the findings can be important when determining immune therapy outcomes in patients with melanoma.

Calder’s 3D Vaxlock technology attained 11 times more effective immune response, compared to typical comparator.

The adjuvanted RSVPreF3 vaccine could prevent nearly 3 million symptomatic RSV-ARI cases among US older adults over 3 years’ time, according to study results.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.

Positive data were presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Disease in Cape Town, South Africa.